Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hamdi Khilfeh

Internal Medicine Evergreen Park, IL Medical Doctor

NPI 1558477661 CMS profile 635184

2955 W. 95Th St, Evergreen Park, IL 60805

Open in the dashboard

General payments

$4,520

218 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hamdi Khilfeh of Evergreen Park, IL is reported in the CMS Open Payments database as having received $4,520 across 218 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $500 24
2024 General $687 32
2023 General $545 26
2022 General $800 42
2021 General $772 33
2020 General $392 21
2019 General $824 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hamdi Khilfeh
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Hamdi Khilfeh were reported at $500. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Hamdi Khilfeh Internal Medicine median Middle half National median
2019 $824 $159 $48–$570 $163
2020 $392 $119 $33–$402 $114
2021 $772 $135 $37–$521 $132
2022 $800 $141 $42–$496 $149
2023 $545 $149 $45–$519 $160
2024 $687 $154 $47–$537 $164
2025 $500 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $766 34 payments
  2. Janssen Pharmaceuticals, Inc $553 22 payments
  3. Lilly USA, LLC $326 15 payments
  4. Novartis Pharmaceuticals Corporation $306 15 payments
  5. Novo Nordisk Inc $305 14 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $160 6 payments
  7. Amgen Inc. $144 8 payments
  8. Pfizer Inc. $130 6 payments
  9. Allergan Inc. $125 6 payments
  10. Astellas Pharma US Inc $123 7 payments
  11. Other $1,585 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,502 216 payments
  2. Education $18 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $553 22 payments
  2. FARXIGA $323 11 payments
  3. MOUNJARO $280 13 payments
  4. Ozempic $274 12 payments
  5. RYBELSUS $232 10 payments
  6. LEQVIO $206 9 payments
  7. AIRSUPRA $173 9 payments
  8. BREZTRI $161 7 payments
  9. AFREZZA $119 6 payments
  10. LOKELMA $107 6 payments
  11. Other $2,890 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 283 drugs

Part D claims

38,385

Median for Internal Medicine: 777

Drug cost

$2,204,471

Median for Internal Medicine: $73,373

Branded share of claims

20.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,706 $464,418
Ozempic Semaglutide Brand 118 $143,833
Farxiga Dapagliflozin Propanediol Brand 146 $118,685
Jardiance Empagliflozin Brand 168 $108,092
Januvia Sitagliptin Phosphate Brand 167 $99,787
Trulicity Dulaglutide Brand 79 $98,457
Xarelto Rivaroxaban Brand 240 $84,954
Tradjenta Linagliptin Brand 294 $69,515
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 12 $52,106
Mounjaro Tirzepatide Brand 39 $44,188

The 10 drugs with the highest cost, of 283 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$616,289

Of which drugs: $3,172

Medicare patients

1,009

Average age 75

Services billed

12,742

577 women, 432 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 56%
Arthritis 55%
Chronic kidney disease 50%
Heart failure 37%
Ischemic heart disease 34%
Depression 32%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 73 73 $1,599
Influenza vaccine, trivalent derived from cell cultures 90661 Office 32 32 $1,156
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 25 590 $133
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 29 75 $73
Injection, ketorolac tromethamine, per 15 mg J1885 Office 12 25 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $118
$118 — —
RECORLEV
  • Xeris Pharmaceuticals, Inc. $92
$92 — —
MOUNJARO
  • Lilly USA, LLC $74
$74 39 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $65
$65 — —
AFREZZA
  • Mannkind Corporation $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

218 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record